Co-Diagnostics, Inc. engages in the development and innovation of molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. The company is headquartered in Salt Lake City, Utah and currently employs 132 full-time employees. The company went IPO on 2017-07-12. The Company’s technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The firm also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious disease. Its diagnostics systems enable dependable, low-cost, molecular testing for organisms and genetic diseases by automating or simplifying historically complex procedures in both the development and administration of tests. The company is developing a portable diagnostic device and test system designed for point-of-care and at-home use. The system consists of its PCR instrument that it refers to as the Co-Dx PCR Pro instrument, its proprietary diagnostic test cup system and a mobile application to be installed on the user’s mobile device.
Follow-Up Questions
Who is the CEO of Co-Diagnostics Inc?
Mr. Dwight Egan is the Chairman of the Board of Co-Diagnostics Inc, joining the firm since 2013.
What is the price performance of CODX stock?
The current price of CODX is $0.3243, it has increased 0.03% in the last trading day.
What are the primary business themes or industries for Co-Diagnostics Inc?
Co-Diagnostics Inc belongs to Health Care industry and the sector is Health Care
What is Co-Diagnostics Inc market cap?
Co-Diagnostics Inc's current market cap is $12.4M
Is Co-Diagnostics Inc a buy, sell, or hold?
According to wall street analysts, 4 analysts have made analyst ratings for Co-Diagnostics Inc, including 2 strong buy, 4 buy, 2 hold, 0 sell, and 2 strong sell
